Home > R&D > Research Alliances
Main contents starts here
Research Alliances
In recent years, pharmaceutical discovery has come to require a combination of technologies from a number of specialized fields. While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.
Research Alliances with overseas research organizations and companies
| Partners | Research subject | Schedule |
| Seattle Genetics (U.S.) |
Research collaboration on Antibody-Drug Conjugate |
Mar 09- |
| Alnylam Pharmaceuticals, Inc. (U.S.) |
Alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. | May 08- May 13 |
| Archemix. Corp. (U.S.) |
Joint research on discovery and development of Aptamer therapeutics. | Jun 07- |
| LG Life Sciences (Korea) |
Joint research on discovery, development commercialize anti- obesity drugs. | Mar 07- Mar 11 |
| XOMA Ltd. (U.S.) |
Joint research on discovery, development and production technologies of monoclonal antibody | Nov 06- |
| Arius Research Inc. (Canada) |
Joint research on functional antibodies in Cancer field | Apr 06- Mar 09 |
| Paradigm Therapeutics (UK) |
Drug discovery alliance in CNS disease | Jul 05- Jun 08 |
| Lexicon Genetics Incorporated (U.S.) |
Joint research on drug target of hypertention | Jul 04- Jul 07 |
| Evotec NeuroSciences (Germany) |
Drug discovery alliance in Alzheimer's disease | Aug 03- Jul 07 |
| Beth Israel Deaconess Medical Center (Harvard Medical School) (U.S.) |
Joint research on drug discovery related to diabetes and obesity | Jul 02- |
| Oxford Centre for Diabetes Endocrinology and Metabolism (UK) |
Partnership with Oxford Diabetes Centre | Apr 02- |
| Gene Logic (U.S.) |
Data base of gene expression (extended target disease since Mar 03) | Mar 02- Dec 06 |
| Array BioPharma (U.S.) |
Joint research on lead compound synthesis | Jul 01- Sep 05 |
| Celera (U.S.) |
Joint research on human genome | Mar 00- Feb 05 |
| WHO (Switzerland) |
Joint research on antimalarial drug discovery | Oct 99- Oct 04 |
Research Alliances with domestic research organizations and companies
| Partners | Research subject | Schedule |
| Osaka University | Development of novel diagnostics of lifestyle-related diseases by novel secretory factors | Apr 04- Mar 07 |
| Kyoto University | Kyoto Cell / Biodynamic Simulation | Oct 03- Mar 08 |
| Kirin Brewery (Now Kyowa Hakko Kirin) | Licensing-in of the human antibody technology | Jul 03 - |
| Keio University | Target discovery for molecules differentiating neuronal stem cells to neurons | Apr 03- Mar 06 |
| RIKEN (The Institute of Physical and Chemical Research) | Analysis of SNPs related to pioglitazone-induced edema | Feb 03- Mar 06 |
| RIKEN (The Institute of Physical and Chemical Research) | Research for human genome relating to osteoarthritis | Jul 02- Mar 05 |
| Keio University | Research for human genome relating to hypertension and diabetic organopathy | Mar 02- Feb 05 |
| Shin Nippon Biomedical Laboratories | Research for toxico-genomics | Jan 02- Jan 06 |
| Biomolecular Engineering Research Institute | Research for application of biomolecular functions | Jun 01- Mar 06 |
| Kagoshima University | Joint research on efficacy evaluation of anti-HIV drugs | Oct 97- Mar 05 |
R&D News
- July 3, 2009
Takeda to hold the commencement ceremony for Construction of New Research Facilities - June 29, 2009
Takeda Submitted an Application for an Additional Indication of Alogliptin for Combination Therapy with Thiazolidinediones, and a New Drug Application of Fixed-Dose Combination of Alogliptin and Pioglitazone HCl in Japan